Therefore, in the present study, in relation to the antileukemic effects of S63845, we also report that inhibition of the MAPK pathway can enhance the pro-apoptotic as well as pro-differentiating activity of this MCL-1 inhibitor in AML cells. This evidence concerns the gene MCL1 and acute myeloid leukemia.